Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2022 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from _______ to _______ Commission File Number: 001-38546 NEURONETICS, INC. (Exact name of registrant as specified in its charter) incorporation or or ...

Financial Data and Key Metrics Changes - Total revenue for Q4 2022 was $18.2 million, an increase of 21% compared to Q4 2021 revenue of $15 million [69] - U.S. NeuroStar Advanced Therapy System revenue was $4.6 million, up 64% from $2.8 million in the prior year [84] - U.S. treatment session revenue reached an all-time record of $12.5 million, an 11% increase over Q4 2021 [70] - Gross margins remained consistent at 76% compared to Q4 2021 [87] - Net loss for Q4 2022 was $8.3 million, compared to a net loss of $7.6 million in Q4 2021 [88] Business Line Data and Key Metrics Changes - The per click consumable segment and other segments are performing well, contributing to the anticipated 20% growth in 2023 [2] - Revenue per active site was approximately $11,500 in Q4 2022, down from approximately $12,200 in the prior year [85] - The number of treatment sessions surpassed 5.3 million across roughly 145,000 patients [67] Market Data and Key Metrics Changes - The company expects to see continued strength from local per click customers despite lower treatment session revenue from certain service providers [90] - The expansion of Medicare coverage and changes in United Health Care's policies are expected to positively impact market access [81] Company Strategy and Development Direction - The company aims to increase customer participation in NeuroStar University and co-op marketing programs to drive growth [49][51] - A focus on creating a network of accounts that follow NeuroStar best practices is planned for 2023 [15] - The company is working to simplify prior authorization processes to expand market access [7] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in achieving 20% growth in 2023, driven by strong performance in non-Greenbrook segments [2][39] - The company does not anticipate recessionary impacts affecting its guidance for 2023 [39] - Management acknowledged the challenges posed by the integration of Greenbrook and Success, which may lead to revenue headwinds [78] Other Important Information - The company shipped over 210 systems in 2022, bringing total systems shipped to over 2,000 [67] - The cash and cash equivalents as of December 31, 2022, were $70.3 million [89] Q&A Session Summary Question: What do you expect out of your core business in 2023? - Management expects growth to be consistent with the second half of 2022, in the 20% range [2] Question: How do you think about the capital versus disposable? - Capital is expected to be consistent with 2022, with 45 to 50 systems anticipated for the year [57] Question: What gets you to the high and low-end of the guidance range? - Management indicated that some contribution from Greenbrook is needed, but growth from other segments should suffice to meet guidance [11] Question: How do you view the impact of coverage policy updates? - Management believes the updates will expand the market and simplify access to care [24] Question: What are the key drivers of treatment session revenue? - The practice development managers and the implementation of PHQ-10s are key drivers of increased utilization [26]

TAP INTO A NEW POSSIBILITY for depression COMPANY PRESENTATION NASDAQ: STIM November 2022 Disclaimers n e u r o s t a r . c o m This presentation contains estimates and other statistical data prepared by independent parties and by Neuronetics, Inc. (the "Company") relating to market size and growth and other data about the industry in which the Company operates. These estimates and data involve a number of assumptions and limitations, and you are cautioned not to give undue weight to such estimates and data ...

Neuronetics, Inc. (NASDAQ:STIM) Q3 2022 Earnings Conference Call November 8, 2022 8:30 AM ET Company Participants Mark Klausner - ICR Westwicke Keith Sullivan - President and Chief Executive Officer Stephen Furlong - Senior Vice President, Chief Financial Officer and Treasurer Conference Call Participants Adam Maeder - Piper Sandler Margaret Kaczor - William Blair Bill Plovanic - Canaccord Marie Thibault - BTIG Operator Good day and thank you for standing by. Welcome to the Neuronetics Report Third Quarter ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2022 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from _______ to _______ Commission File Number: 001-38546 NEURONETICS, INC. (Exact name of registrant as specified in its charter) incorporat ...

Revenue Performance - Total revenues increased by $2.1 million, or 15%, from $14.2 million for the three months ended June 30, 2021, to $16.3 million for the same period in 2022[113]. - U.S. revenues for the three months ended June 30, 2022, were $16.1 million, representing a 17% increase compared to $13.8 million for the same period in 2021[113]. - Total revenue for the three months ended June 30, 2022 was $16.3 million, an increase of 15% compared to $14.2 million for the same period in 2021[132]. - Total revenue for the six months ended June 30, 2022 was $30.5 million, an increase of 15% compared to $26.5 million for the same period in 2021[147]. - U.S. NeuroStar Advanced Therapy System revenue for the six months ended June 30, 2022 was $8.0 million, an increase of 85% compared to $4.3 million in the same period in 2021[148]. Losses and Financial Condition - The company incurred net losses of $10.4 million and $21.3 million for the three and six months ended June 30, 2022, compared to net losses of $7.5 million and $15.4 million for the same periods in 2021[113]. - Net loss for the three months ended June 30, 2022 was $10.4 million, a 38% increase compared to a net loss of $7.5 million in the same period in 2021[130]. - The company reported a net loss of $21.3 million for the six months ended June 30, 2022, primarily due to an increase in net operating assets[164]. - The company has incurred operating losses since inception and expects these losses to continue in the near term as it expands sales and marketing initiatives[157]. Revenue Sources - Revenues from sales of Treatment Sessions and NeuroStar Advanced Therapy Systems represented 70% and 27% of U.S. revenues for the three months ended June 30, 2022[108]. - The NeuroStar Advanced Therapy System has treated over 134,300 global patients with over 4.8 million treatment sessions to date[107]. - International revenues represented 1% and 3% of total revenues for the three months ended June 30, 2022, and 2021, respectively[110]. - International revenue decreased by 50% to $197,000 for the three months ended June 30, 2022, primarily due to a decline in international NeuroStar Advanced Therapy System sales[132]. Expenses and Investments - The company plans to increase research and development expenses to continue developing TMS Therapy for additional patient populations and new indications[127]. - The company anticipates that sales and marketing expenses will increase in 2022 compared to 2021 as it executes growth initiatives[123]. - Sales and marketing expenses increased by 51% to $13.7 million for the three months ended June 30, 2022, primarily due to new marketing initiatives[136]. - Research and development expenses decreased by 16% to $3.8 million for the six months ended June 30, 2022, due to reduced product development costs[153]. Cash Flow and Financing - As of June 30, 2022, the company had cash and cash equivalents of $70.9 million, down from $94.1 million as of December 31, 2021, and an accumulated deficit of $330.0 million[157]. - The company incurred negative cash flows from operating activities of $21.1 million for the six months ended June 30, 2022, compared to $14.9 million for the same period in 2021[157]. - Net cash used in investing activities for the six months ended June 30, 2022, was $2.0 million, an increase from $1.1 million in 2021, primarily due to purchases of property and equipment and capitalized software costs[166]. - The company had $35.0 million of borrowings outstanding under its credit facility as of June 30, 2022, with a final maturity in February 2025[157]. - The company anticipates that its cash and cash equivalents, along with expected revenues, will be sufficient to fund operations for at least 12 months from the issuance of the financial statements[157]. - The company may seek additional funding through equity or debt financing if cash and anticipated revenues are insufficient, which could lead to dilution for existing shareholders[158]. Market Conditions - The company continues to monitor inflationary factors that may affect operating results, although it does not believe inflation has materially impacted its financial condition to date[175].

Neuronetics Inc (NASDAQ:STIM) Q2 2022 Earnings Conference Call August 2, 2022 8:30 AM ET Company Participants Mark Klausner - Investor Relations Keith Sullivan - President & CEO Steve Furlong - SVP, CFO & Treasurer Conference Call Participants Adam Maeder - Piper Sandler Margaret Kaczor - William Blair William Plovanic - Canaccord Genuity Marie Thibault - BTIG David Turkaly - JMP Securities Operator Good day, and thank you for standing by. Welcome to the Neuronetics' Reports Second Quarter 2022 Financial an ...

TAP INTO A NEW POSSIBILITY for depression COMPANY PRESENTATION NASDAQ: STIM August 2022 Disclaimers neurostar.com This presentation contains estimates and other statistical data prepared by independent parties and by Neuronetics, Inc. (the "Company") relating to market size and growth and other data about the industry in which the Company operates. These estimates and data involve a number of assumptions and limitations, and you are cautioned not to give undue weight to such estimates and data. Certain stat ...

TAP INTO A NEW POSSIBILITY for depression COMPANY PRESENTATION NASDAQ: STIM May 2022 Disclaimers n e u r o s t a r . c o m This presentation contains estimates and other statistical data prepared by independent parties and by Neuronetics, Inc. (the "Company") relating to market size and growth and other data about the industry in which the Company operates. These estimates and data involve a number of assumptions and limitations, and you are cautioned not to give undue weight to such estimates and data. Cer ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2022 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from _______ to _______ Commission File Number: 001-38546 NEURONETICS, INC. (Exact name of registrant as specified in its charter) incorporation ...